Green Cross, Abraxis BioScience enter cross licensing agreement

Published: 2007-11-30 06:58:00

Updated: 2007-11-30 06:58:00

Green Cross Corporation and U.S.-based Abraxis BioScience Inc, an integrated and global biopharmaceutical company, announced on November 27 an agreement for the development and commercialization of GCC's five new products, including recombinant blood coagulant XIII factor, interferon alpha and immunopotentiator in the United States.

The agreement was executed between GCC's vice chairman Huh ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.